Tokyo, Japan – March 25, 2021 – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that as the company now enters the next phase of growth, Ken Takeshita, MD, in his new role as Global Head of Research and Development, will directly oversee research and development for the entire Daiichi Sankyo portfolio.  Having successfully led Daiichi Sankyo’s journey toward having a “competitive advantage in Oncology” over the last 5 years,  it is now the appropriate time for Antoine Yver, MD, MSc to step out of his full-time role as Executive VP and Global Head, Oncology R&D at the end of May 2021. After May 31, 2021, Antoine will become a special advisor to Dr. Takeshita until July 31, 2021. We would like to thank Antoine for his significant contributions and dedication to Daiichi Sankyo and the patients we serve, and wish him the best of luck with all of his future endeavors.